# Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

> **NCT01258387** · PHASE1 · COMPLETED · sponsor: **Acorda Therapeutics** · enrollment: 40 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Glial growth factor 2/ Neuregulin 1β3
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01258387
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-12
- **Final completion:** 2013-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01258387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01258387, "Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01258387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*